Compare ADMA Biologics Inc (ADMA) vs Wipro Limited (WIT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Wipro Limited — how do they compare? ADMA Biologics Inc trades at $9.28 (market cap $2.13B), while Wipro Limited trades at $1.85 (market cap $18.14B). The key difference: Wipro Limited is far larger — about 8.5× ADMA Biologics Inc's market cap, and Wipro Limited pays a 10.37% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | WIT | |
|---|---|---|
Market Cap | $2.13B | $18.14B |
Sector | Health | Technology |
52-Week High | $20.38 | $3.09 |
52-Week Low | $7.60 | $1.82 |
Enterprise Value | $2.20B | $14.53B |
Dividend Yield | — | 10.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
WIT trades at $1.85, down 2.12% today, with a bearish technical signal from moving averages. The company reported revenue of $890.88B in 2025 with a net income margin of 14.25% and a P/E ratio of 13.82. Recent earnings have missed estimates for three consecutive quarters, and analyst sentiment is mixed with a Hold consensus. News highlights include AI partnerships and a weak Q2 2026 revenue outlook.
The outlook is cautious due to near-term revenue pressure and earnings misses, though valuation appears reasonable. Risks include client spending caution and competitive pressures. Upside may depend on AI-driven growth initiatives and large deal execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Wipro Limited
Wipro is a leading global IT services provider, with 175,000 employees. Based in Bengaluru, this India IT services firm leverages its offshore outsourcing model to derive over half of its revenue (57%) from North America. The company offers traditional IT services offerings: consulting, managed services, and cloud infrastructure services as well as business process outsourcing as a service.
Read more on WIT →
